In the MRC cohort, CBF‐AML patients who completed all FLAG‐ and HDAC‐based induction/consolidations had stellar outcomes37 In our cohort also on comparing TTNT between Groups 1 and 2; there was a significant difference in the OS and there was a trend toward significance in TTNT between these two groups. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.